Advertisement
U.S. Markets open in 7 hrs 51 mins

Nxera Pharma Co., Ltd. (SOLTF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed Price. Currency in USD
8.050.00 (0.00%)
At close: 03:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.00
Open7.75
Bid7.80 x 40000
Ask7.30 x 40000
Day's Range7.75 - 7.75
52 Week Range7.00 - 13.43
Volume110
Avg. Volume121
Market Cap723.884M
Beta (5Y Monthly)0.63
PE Ratio (TTM)N/A
EPS (TTM)-0.27
Earnings DateFeb 11, 2025 - Feb 17, 2025
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 27, 2015
1y Target EstN/A
  • GlobeNewswire

    Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

    Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). The collaboration combines Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-s

  • GlobeNewswire

    Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024

    Tokyo, Japan and Cambridge, UK, 1 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended on 30 September 2024. The full report can be viewed here. Chris Cargill, President & CEO of Nxera, commented: “The third quarter of 2024 has seen Nxera reach two important product development milestones. First, i